Dr. Nicholas A. Butowski on Convection-Enhanced Delivery of Nanoliposomal Irinotecan in Brain Cancer
Nicholas A. Butowski, MD, director, Translational Research in Neuro-Oncology, University of California, San Francisco, discusses the eligibility of patients with glioblastoma to receive a convection-enhanced delivery of nanoliposomal irinotecan with real-time imaging.
Nicholas A. Butowski, MD, director, Translational Research in Neuro-Oncology, University of California, San Francisco, discusses the eligibility of patients with glioblastoma to receive a convection-enhanced delivery of nanoliposomal irinotecan with real-time imaging.
Butowski encourages any medical professional who is treating a patient with either a grade 3 or 4 recurrent brain tumor to refer that patient to an institution to receive nanoliposomal irinotecan. He adds while the treatment may take 2 or 3 hours, depending on the patient, the treatment is targeted with an MRI so medical professionals can be as accurate as possible.
